The prognostic value of MGMT promoter methylation in glioblastoma: A meta‐analysis of clinical trials

The DNA repair protein O6‐Methylguanine‐DNA methyltransferase (MGMT) is suggested to be associated with resistance to alkylating agents such as Temozolomide which is being used in treatment of patients with glioblastoma (GBM). Therefore, we evaluated the associations between MGMT promoter methylation and prognosis of patients with glioblastoma (GBM). Data were extracted from publications in Embase, PubMed, and the Cochrane Library. Data on overall survival (OS), progression‐free survival (PFS), and MGMT methylation status were obtained and 4,097 subjects were enrolled. Data from 34 studies showed that MGMT methylated patients had better OS, compared to GBM unmethylated patients (pooled HRs, 0.494; 95%CI 0.412–0.591; p = 0.001). Meta‐analysis of 10 eligible studies reporting on PFS, demonstrated that MGMT promoter methylation was not significantly associated with better PFS (pooled HRs, 0.653; 95%CI 0.414–1.030; p = 0.067). GBM patients with MGMT methylation were associated with longer overall survival, although this effect was not detected for PFS. Moreover, we performed further analysis in patients underwent a comprehensive imaging evaluation. This data showed a significant association with better OS and PFS, although further studies are warranted to assess the value of emerging marker in prospective setting in patients with glioblastoma as a risk stratification biomarker in clinical management of the patients.

[1]  T. Jacques,et al.  The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know. , 2016, Quantitative imaging in medicine and surgery.

[2]  A. Fiorentino,et al.  Can Elderly Patients With Newly Diagnosed Glioblastoma be Enrolled in Radiochemotherapy Trials? , 2015, American journal of clinical oncology.

[3]  Walter J Curran,et al.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Jerry J. Lou,et al.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. , 2013, Neuro-oncology.

[5]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[6]  G. Reifenberger,et al.  Predictive impact of MGMT promoter methylation in glioblastoma of the elderly , 2012, International journal of cancer.

[7]  J. Golfinos,et al.  A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. , 2012, Journal of neurosurgery.

[8]  Andreas von Deimling,et al.  Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? , 2011, Radiation oncology.

[9]  V. Esposito,et al.  Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide , 2011, Journal of Neuro-Oncology.

[10]  H. Kretzschmar,et al.  Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  S. Konduri,et al.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. , 2010, Neuro-oncology.

[12]  M. Honavar,et al.  Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. , 2010, Oncology reports.

[13]  Stephan Saikali,et al.  Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods , 2010, Journal of Neuro-Oncology.

[14]  T. Tominaga,et al.  O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma , 2010, International Journal of Clinical Oncology.

[15]  A. Brandes,et al.  Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference , 2010, BMC Cancer.

[16]  Howard Colman,et al.  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.

[17]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. J. van den Bent,et al.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Iafrate,et al.  MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA , 2009, Neurology.

[21]  Shin Jung,et al.  THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMAS , 2009, Neurosurgery.

[22]  R. Fimmers,et al.  Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.

[23]  O. Chinot,et al.  Prognostic impact of O6‐methylguanine‐DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation , 2009, Cancer.

[24]  L. Deangelis,et al.  Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Chae-Yong Kim,et al.  Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[26]  A. Brodbelt,et al.  Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy , 2009, British Journal of Cancer.

[27]  J. Rahnenführer,et al.  p15 promoter methylation - a novel prognostic marker in glioblastoma patients. , 2009, International journal of oncology.

[28]  Miguel Alaminos,et al.  A microarray-based DNA methylation study of glioblastoma multiforme , 2009, Epigenetics.

[29]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[30]  S. Franceschi,et al.  Common Polymorphisms in the MDM2 and TP53 Genes and the Relationship between TP53 Mutations and Patient Outcomes in Glioblastomas , 2009, Brain pathology.

[31]  Allan H Friedman,et al.  Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Martin Glas,et al.  Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Brandes,et al.  Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Franceschi,et al.  Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study , 2008, Neuroepidemiology.

[35]  J. Cairncross,et al.  Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme , 2008, Journal of Neuro-Oncology.

[36]  G. Broggi,et al.  Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival , 2007, Clinical Cancer Research.

[37]  I. Ferrer,et al.  Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas , 2005, Clinical Cancer Research.

[38]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[39]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[40]  N. Shinojima,et al.  Correlation between Promoter Hypermethylation of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene and Prognosis in Patients with High-grade Astrocytic Tumors Treated with Surgery, Radiotherapy, and 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based Chemot , 2004, Neurosurgery.

[41]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[42]  設楽 兼司,et al.  胃癌におけるO^6-Methylguanine-DNA Methyltransferase(MGMT)発現 , 2002 .

[43]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[44]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[45]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[46]  K. Mineura,et al.  Human brain tumor O6‐methylguanine‐DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy , 1996, International journal of cancer.

[47]  M. Berger,et al.  Contribution of O6‐methylguanine‐DNA methyltransferase to resistance to 1,3‐(2‐chloroethyl)‐1‐nitrosourea in human brain tumor‐derived cell lines , 1995, Molecular carcinogenesis.

[48]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[49]  J. Hendry,et al.  Radiobiology for the Radiologist , 1979, British Journal of Cancer.

[50]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[51]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[52]  A. Friedman,et al.  Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. , 2012, International journal of radiation oncology, biology, physics.

[53]  M. Bernaudin,et al.  O-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated With Biodegradable Carmustine Wafer Implants After Initial Surgery Followed by Radiotherapy With Concomitant and Adjuvant Temozolomide , 2012 .

[54]  G. Schackert,et al.  A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Y. Katayama,et al.  O-Methylguanine-DNA Methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course , 2004 .

[56]  Bias in meta›analysis detected by a simple, graphical test , 1998 .

[57]  A. Giaccia,et al.  Radiobiology for the radiologist , 1973 .